Innova Captab Limited has informed the Exchange regarding a press release dated August 07, 2025, titled "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, ( SEBI LODR Regulations ), we are enclosing herewith the Press Release issued by the Company on the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2025. The Press Release is available on the website of the Company.
INNOVACAP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Innova Captab Limited, a pharmaceutical company, announced its Q1 FY26 results (quarter ended June 30, 2025). Revenue from Operations grew 19% year-on-year to ₹351.5 crore, driven by new products including those from the newly commissioned Jammu plant and market expansion. Consolidated EBITDA rose 28% YoY to ₹56.6 crore, with EBITDA margins improving to 16.1% from 15.1% (100 bps expansion) supported by better gross margins. Profit After Tax increased 5% YoY to ₹31.0 crore, with PAT margin at 8.8%, despite higher depreciation and finance expenses. The company has reorganized its business into two focused verticals — CDMO and Branded Generics — to align with its strategic vision.
Strong revenue and EBITDA growth with margin expansion signals healthy operational performance, though muted PAT growth (5%) due to higher depreciation and finance costs may temper near-term enthusiasm. The ramp-up of the Jammu facility and business reorganization into CDMO and Branded Generics verticals are positive long-term signals for sustainable growth.